Dunn RM - Search Results

1

Phase I/II clinical radioimmunotherapy with an iodine-131-labeled anti-carcinoembryonic antigen murine monoclonal antibody IgG.

Behr TM, Sharkey RM, Juweid ME, Dunn RM, Vagg RC, Ying Z, Zhang CH, Swayne LC, Vardi Y, Siegel JA, Goldenberg DM. Behr TM, et al. Among authors: dunn rm. J Nucl Med. 1997 Jun;38(6):858-70. J Nucl Med. 1997. PMID: 9189130 Free article. Clinical Trial.

2

Factors influencing the pharmacokinetics, dosimetry, and diagnostic accuracy of radioimmunodetection and radioimmunotherapy of carcinoembryonic antigen-expressing tumors.

Behr TM, Sharkey RM, Juweid MI, Dunn RM, Ying Z, Zhang CH, Siegel JA, Gold DV, Goldenberg DM. Behr TM, et al. Among authors: dunn rm. Cancer Res. 1996 Apr 15;56(8):1805-16. Cancer Res. 1996. PMID: 8620497

3

Thyroid radiation doses during radioimmunotherapy of CEA-expressing tumours with 131I-labelled monoclonal antibodies.

Behr TM, Juweid ME, Sharkey RM, Dunn RM, Ying Z, Becker WS, Siegel JA, Goldenberg DM. Behr TM, et al. Among authors: dunn rm. Nucl Med Commun. 1996 Sep;17(9):767-80. doi: 10.1097/00006231-199609000-00007. Nucl Med Commun. 1996. PMID: 8895904

4

Reduction of renal uptake of monoclonal antibody fragments by amino acid infusion.

Behr TM, Becker WS, Sharkey RM, Juweid ME, Dunn RM, Bair HJ, Wolf FG, Goldenberg DM. Behr TM, et al. Among authors: dunn rm. J Nucl Med. 1996 May;37(5):829-33. J Nucl Med. 1996. PMID: 8965154 Free article. Clinical Trial.

5

Variables influencing tumor dosimetry in radioimmunotherapy of CEA-expressing cancers with anti-CEA and antimucin monoclonal antibodies.

Behr TM, Sharkey RM, Juweid ME, Dunn RM, Ying Z, Zhang CH, Siegel JA, Goldenberg DM. Behr TM, et al. Among authors: dunn rm. J Nucl Med. 1997 Mar;38(3):409-18. J Nucl Med. 1997. PMID: 9074529 Free article.

6

99Tcm-LL1: a potential new bone marrow imaging agent.

Juweid M, Dunn RM, Sharkey RM, Rubin AD, Hansen HJ, Goldenberg DM. Juweid M, et al. Among authors: dunn rm. Nucl Med Commun. 1997 Feb;18(2):142-8. Nucl Med Commun. 1997. PMID: 9076770

7

Advantage of residualizing radiolabels for an internalizing antibody against the B-cell lymphoma antigen, CD22.

Sharkey RM, Behr TM, Mattes MJ, Stein R, Griffiths GL, Shih LB, Hansen HJ, Blumenthal RD, Dunn RM, Juweid ME, Goldenberg DM. Sharkey RM, et al. Among authors: dunn rm. Cancer Immunol Immunother. 1997 May;44(3):179-88. doi: 10.1007/s002620050371. Cancer Immunol Immunother. 1997. PMID: 9191878 Free PMC article.

8

Cancer imaging with radiolabeled antibodies: new advances with technetium-99m-labeled monoclonal antibody Fab' fragments, especially CEA-Scan and prospects for therapy.

Goldenberg DM, Juweid M, Dunn RM, Sharkey RM. Goldenberg DM, et al. Among authors: dunn rm. J Nucl Med Technol. 1997 Mar;25(1):18-23; quiz 34. J Nucl Med Technol. 1997. PMID: 9239599 Review.

9

Overcoming the nephrotoxicity of radiometal-labeled immunoconjugates: improved cancer therapy administered to a nude mouse model in relation to the internal radiation dosimetry.

Behr TM, Sharkey RM, Sgouros G, Blumenthal RD, Dunn RM, Kolbert K, Griffiths GL, Siegel JA, Becker WS, Goldenberg DM. Behr TM, et al. Among authors: dunn rm. Cancer. 1997 Dec 15;80(12 Suppl):2591-610. doi: 10.1002/(sici)1097-0142(19971215)80:12+<2591::aid-cncr35>3.3.co;2-a. Cancer. 1997. PMID: 9406714

10

Can occult metastases be treated by radioimmunotherapy?

Dunn RM, Juweid M, Sharkey RM, Behr TM, Goldenberg DM. Dunn RM, et al. Cancer. 1997 Dec 15;80(12 Suppl):2656-9. doi: 10.1002/(sici)1097-0142(19971215)80:12+<2656::aid-cncr42>3.3.co;2-4. Cancer. 1997. PMID: 9406721

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

107 results

Search Page

Filters